740168
Last Update Posted: 2016-01-21
Recruiting has ended
All Genders accepted | 18 Years + |
20 Estimated Participants | No Expanded Access |
Observational Study | Does not accept healthy volunteers |
Bevacizumab Treatment and Retinal Vessel Monitoring
Bevacizumab might influence the dynamic vessel function after being administered intravenously.
By monitoring different vessel and circulation parameters (e.g. dynamic retinal vessel analyzer) the study will clarify the potential hemodynamic effects of bevacizumab.
Eligibility
Relevant conditions:
Cancer
If you aren't sure if you meet the criteria above speak to your healthcare professional. Criteria may be updated but not reflected here, do not hesitate to contact the study if you think are close to fitting criteria.
locations
Data sourced from ClinicalTrials.gov